Phase 3 Recruiting NIH
This phase III trial compares the effect of adding immunotherapy (brentuximab vedotin and nivolumab) to standard treatment (chemotherapy with or without radiation) to the standard treatment alone in improving survival in patients with stag…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05675410
Sites in Missouri: - Saint Francis Medical Center — Cape Girardeau, Missouri
- Saint Luke's Hospital — Chesterfield, Missouri
- Siteman Cancer Center at Saint Peters Hospital — City of Saint Peters, Missouri
- University of Missouri Children's Hospital — Columbia, Missouri
- Siteman Cancer Center at West County Hospital — Creve Coeur, Missouri
Phase 3 Recruiting Network
This phase III trial compares the effect of adding levocarnitine to standard chemotherapy versus (vs.) standard chemotherapy alone in protecting the liver in patients with leukemia or lymphoma. Asparaginase is part of the standard of care …
Sponsor: Children's Oncology Group
NCT ID: NCT05602194
Sites in Missouri: - Children's Mercy Hospitals and Clinics — Kansas City, Missouri
- Mercy Hospital Saint Louis — St Louis, Missouri
Phase 3 Recruiting Industry
Follicular lymphoma (FL) is the second most common B-cell cancer and the most common type of cancer of lymphocytes. Unfortunately, this disease is incurable with conventional treatment and the disease recurs in almost all patients. This st…
Sponsor: Genmab
NCT ID: NCT06191744
Sites in Missouri: - St. Luke's Hospital - Chesterfield /ID# 260489 — Chesterfield, Missouri
Phase 3 Recruiting Industry
The purpose of the study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab (R\^2) in participants with relapsed/refractory (R/R) follicular lymphoma (FL), as measured by progression-free surviv…
Sponsor: BeiGene
NCT ID: NCT05100862
Sites in Missouri: - University of Missouri Hospital, Ellis Fischel Cancer Center — Columbia, Missouri
- Oncology Hematology Associates — Springfield, Missouri
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of geriatric evaluation and management with survivorship health education (GEM-S) to usual care on patient-reported physical function in older survivors of cancer. Survivorship care for older adults…
Sponsor: University of Rochester
NCT ID: NCT05006482
Sites in Missouri: - Lake Regional Hospital — Osage Beach, Missouri
Phase 3 Recruiting Industry
The goal of this study is to evaluate nemtabrutinib compared with investigator's choice of ibrutinib or acalabrutinib in participants with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have not received any prior …
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136559
Sites in Missouri: - MidAmerica Cancer Care, LLC ( Site 0043) — Kansas City, Missouri
Phase 3 Recruiting Industry
The purpose of this study is to evaluate if zilovertamab vedotin with standard treatment can help people live longer without the cancer growing or spreading than people who receive standard treatment alone.
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06717347
Sites in Missouri: - Circuit Clinical - SSM Health Cancer Care DePaul ( Site 0166) — Bridgeton, Missouri
- Truman Medical Center ( Site 0122) — Kansas City, Missouri
Phase 3 Recruiting Industry
The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolled in ibrutinib studies that have been c…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT01804686
Sites in Missouri: - Washington University — St Louis, Missouri
Phase 3 Recruiting Industry
The purpose of this study is to investigate the efficacy and safety of BGB-16673 compared with investigator's choice (idelalisib plus rituximab \[for CLL only\] or bendamustine plus rituximab or venetoclax plus rituximab retreatment) in pa…
Sponsor: BeOne Medicines
NCT ID: NCT06846671
Sites in Missouri: - Oncology Hematology Associates — Springfield, Missouri
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy of glofitamab monotherapy compared with an investigator's choice of either rituximab plus bendamustine (BR), or lenalidomide with rituximab (R-Len) in patients with relapsed or refracto…
Sponsor: Hoffmann-La Roche
NCT ID: NCT06084936
Sites in Missouri: - St. Luke's Hospital — Chesterfield, Missouri
Phase 3 Recruiting Industry
To evaluate the use of HyBryte, a topical photosensitizing agent, to treat patients with patch/plaque phase cutaneous T-cell lymphoma (mycosis fungoides).
Sponsor: Soligenix
NCT ID: NCT06470451
Sites in Missouri: - Washington University — St Louis, Missouri
Phase 3 Recruiting Academic/Other
Nationally, the opioid crisis has become a major epidemic with increasing mortality rates each year. Orthopedic surgeons routinely prescribe narcotics instead of NSAIDs for post-op pain control because of risk of delayed healing and nonuni…
Sponsor: St. Louis University
NCT ID: NCT03823534
Sites in Missouri: - Saint Louis University — St Louis, Missouri
Phase 2 Recruiting NIH
This phase II trial studies how well inotuzumab ozogamicin and blinatumomab with or without ponatinib work in treating patients with CD22-positive B-lineage acute lymphoblastic leukemia that is newly diagnosed, has come back after a period…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03739814
Sites in Missouri: - Mercy Oncology and Hematology - Clayton-Clarkson — Ballwin, Missouri
- Central Care Cancer Center - Bolivar — Bolivar, Missouri
- Cox Cancer Center Branson — Branson, Missouri
- Mercy Cancer Center - Cape Girardeau — Cape Girardeau, Missouri
- Saint Francis Medical Center — Cape Girardeau, Missouri
Phase 2 Recruiting NIH
This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04546399
Sites in Missouri: - Children's Mercy Hospitals and Clinics — Kansas City, Missouri
- Cardinal Glennon Children's Medical Center — St Louis, Missouri
- Washington University School of Medicine — St Louis, Missouri
- Mercy Hospital Saint Louis — St Louis, Missouri
Phase 1, Phase 2 Recruiting Academic/Other
This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back a…
Sponsor: PedAL BCU, LLC
NCT ID: NCT04726241
Sites in Missouri: - University of Missouri Children's Hospital — Columbia, Missouri
- Children's Mercy Hospitals and Clinics — Kansas City, Missouri
- Cardinal Glennon Children's Medical Center — St Louis, Missouri
- Washington University School of Medicine — St Louis, Missouri
- Mercy Hospital Saint Louis — St Louis, Missouri
Phase 2 Recruiting NIH
This phase II trial studies the effects of venetoclax and rituximab in comparison to ibrutinib and rituximab or zanubrutinib in treating patients with previously untreated Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma. Ibrutin…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04840602
Sites in Missouri: - Saint Francis Medical Center — Cape Girardeau, Missouri
- Siteman Cancer Center at Saint Peters Hospital — City of Saint Peters, Missouri
- Siteman Cancer Center at West County Hospital — Creve Coeur, Missouri
- Heartland Regional Medical Center — Saint Joseph, Missouri
- Washington University School of Medicine — St Louis, Missouri
Phase 2 Recruiting NIH
This phase II trial tests the addition of venetoclax and/or blinatumomab to usual chemotherapy for treating infants with newly diagnosed acute lymphoblastic leukemia (ALL) with a KMT2A gene rearrangement (KMT2A-rearranged \[R\]) or without…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06317662
Sites in Missouri: - Children's Mercy Hospitals and Clinics — Kansas City, Missouri
- Washington University School of Medicine — St Louis, Missouri
- Mercy Hospital Saint Louis — St Louis, Missouri
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the best dose, side effects and possible benefit of CBL0137 in treating patients with solid tumors, including central nervous system (CNS) tumors or lymphoma that has come back (relapsed) or does not respond…
Sponsor: Children's Oncology Group
NCT ID: NCT04870944
Sites in Missouri: - Children's Mercy Hospitals and Clinics — Kansas City, Missouri
- Washington University School of Medicine — St Louis, Missouri
Phase 2 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of ibrutinib + venetoclax (I+V) and ibrutinib monotherapy regimens in which dosing of ibrutinib is either proactively reduced or reactively modified in response to adverse ev…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT05963074
Sites in Missouri: - Research Medical Center — Kansas City, Missouri
Phase 2 Recruiting Industry
The purpose of this study is to evaluate the safety and efficacy of lisocabtagene maraleucel (Breyanzi/liso-cel/BMS-986387) in adults as first-line treatment in transplant-ineligible Primary Central Nervous System Lymphoma (PCNSL).
Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
NCT ID: NCT07015242
Sites in Missouri: - Local Institution - 316 — St Louis, Missouri
- Washington University School of Medicine in St. Louis — St Louis, Missouri
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interf…
Sponsor: Children's Oncology Group
NCT ID: NCT04851119
Sites in Missouri: - Washington University School of Medicine — St Louis, Missouri
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to measure the safety, preliminary antitumor activity, pharmacokinetics, and pharmacodynamics with BGB-16673 in combination with other agents in participants with relapsed or refractory (R/R) B-cell malignancie…
Sponsor: BeOne Medicines
NCT ID: NCT06634589
Sites in Missouri: - Washington University School of Medicine — St Louis, Missouri
Phase 2 Recruiting Industry
This study will assess the efficacy and safety of bilateral intra-parotid administration of AAV2-hAQP1 in adults with Grade 2 or Grade 3 radiation-induced late xerostomia.
Sponsor: MeiraGTx, LLC
NCT ID: NCT05926765
Sites in Missouri: - University of Missouri — Columbia, Missouri
- Washington University - St. Louis — St Louis, Missouri
Phase 1, Phase 2 Recruiting Industry
Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab vedotin in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse lar…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06395103
Sites in Missouri: - Children's Mercy Hospital ( Site 1024) — Kansas City, Missouri
Phase 2 Recruiting Industry
The T-RRex study evaluates the efficacy of WU-CART-007 for patients with Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL)/Lymphoblastic Lymphoma (LBL) and to WU-CART-007 as a therapy to induce complete Minimum Residual…
Sponsor: Wugen, Inc.
NCT ID: NCT06514794
Sites in Missouri: - Washington University Saint Louis — St Louis, Missouri